Velika Britanija - engleski - MHRA (Medicines & Healthcare Products Regulatory Agency)

kent pharma (uk) ltd - desferrioxamine mesilate - powder for solution for injection - 500mg

Velika Britanija - engleski - MHRA (Medicines & Healthcare Products Regulatory Agency)

kent pharma (uk) ltd - desferrioxamine mesilate - powder for solution for injection - 2gram

Velika Britanija - engleski - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - desferrioxamine mesilate - eye drops - 100mg/1ml

Velika Britanija - engleski - MHRA (Medicines & Healthcare Products Regulatory Agency)

novartis pharmaceuticals uk ltd - desferrioxamine mesilate - powder for solution for injection - 500mg

Velika Britanija - engleski - MHRA (Medicines & Healthcare Products Regulatory Agency)

novartis pharmaceuticals uk ltd - desferrioxamine mesilate - powder for solution for injection - 2gram

Singapur - engleski - HSA (Health Sciences Authority)

pfizer private limited - desferrioxamine mesylate - injection, powder, for solution - 500 mg/vial - desferrioxamine mesylate 500 mg/vial

Novi Zeland - engleski - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - deferoxamine mesilate 2 g - powder for injection - 2 g - active: deferoxamine mesilate 2 g - monotherapy iron chelation treatment for chronic iron overload, e.g. · transfusional haemosiderosis, as seen in thalassaemia major, sideroblastic anaemia, auto-mmune haemolytic anaemia, and other chronic anaemias. · idiopathic (primary) haemochromatosis in patients in whom concomitant disorders (e.g. severe anaemia, cardiac disease, hypoproteinaemia) preclude phlebotomy · iron overload associated with porphyria cutanea tarda in patients unable to tolerate phlebotomy. · treatment for acute iron poisoning.

Novi Zeland - engleski - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - deferoxamine mesilate 500mg - powder for injection - 500 mg - active: deferoxamine mesilate 500mg - monotherapy iron chelation treatment for chronic iron overload, e.g. · transfusional haemosiderosis, as seen in thalassaemia major, sideroblastic anaemia, auto-mmune haemolytic anaemia, and other chronic anaemias. · idiopathic (primary) haemochromatosis in patients in whom concomitant disorders (e.g. severe anaemia, cardiac disease, hypoproteinaemia) preclude phlebotomy · iron overload associated with porphyria cutanea tarda in patients unable to tolerate phlebotomy. · treatment for acute iron poisoning.

Malta - engleski - Medicines Authority

mercury pharma international limited 4045 kingswood road, city west business park, co, dublin, ireland - prochlorperazine mesilate - solution for injection - prochlorperazine mesilate 12.5 mg/ml - psycholeptics

Australija - engleski - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - desferrioxamine mesylate -